drugset / Trial / NCT06902025
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL).
Timeline
- Start
- 2025-03-31
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JY231 | Cell therapy | — | Intravenous |
Indications
No indication recorded.